Reliable biomarkers predictive of venous thromboembolism (VTE) after acute trauma are uncertain. The objective of the study was to identify risk factors for symptomatic VTE after trauma, including individual plasma coagulome characteristics as reflected by thrombin generation.
T he overall incidence of venous thromboembolism (VTE) remained relatively unchanged at about 1.2 per 1,000 between 1981 and 2010. [1] [2] [3] [4] Likewise, after trauma, the incidence of pulmonary embolism has more than doubled during the period of 2007 to 2009 as compared to an earlier period (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) . 5 Although the Joint Commission, CMS, and the Surgeon General recommend assessment of the risk of VTE for every hospitalized patient, our rudimentary understanding of mechanisms contributing to VTE has precluded development of reliable biomarkers and standardized screening procedures to identify the individual at high risk for VTE. Previously identified clinical risk factors for VTE after trauma have a low predictive value for the individual patient; fatal VTE may occur despite a presumed low risk profile. Hence, there is critical need for identifying the high-VTE-risk individual trauma patient to decrease the risk of bleeding complications 6 or infection 7, 8 from the use of anticoagulant-based prophylaxis in the low-VTE-risk individual.
To assess an individual patient's coagulation phenotype, we used the calibrated automated thrombogram (CAT) to quantify the kinetics of plasma thrombin generation. 9, 10 The plasma procoagulant system is a "cascade" of enzymatic reactions triggered by exposure of blood to tissue factor (TF) released after trauma, ultimately resulting in the generation of thrombin. Thrombin cleaves plasma fibrinogen to produce insoluble fibrin and activates platelets that cohere with fibrin to produce a thrombus (clot). CAT is a rapid, sensitive method to quantify in real time plasma thrombin generation in response to TF and procoagulant phospholipid (PS). Compared to traditional clotting assays, such as the prothrombin time (PT) and activated partial thromboplastin time (aPTT), which yield only one time point and evaluate clot formation early in the process of thrombin generation, CAT provides the total amount of thrombin generated and the peak rate of thrombin generation in an individual's plasma. Thus, CAT is a global measure of an individual's plasma coagulome. Patients with clinical risk factors for VTE (obesity, increasing age, oral contraceptives) have increased total thrombin generation, [11] [12] [13] and importantly, total thrombin generation has been shown to be an independent predictor of recurrent VTE.
14 CAT parameters include lagtime (initiation phase of clotting; minutes), peak height (maximal amount of thrombin generated; nM), and time to peak thrombin (reflects rate of thrombin generation; ttPeak, minutes). Theoretically, "hypercoagulable" trauma-induced coagulopathy (TIC) would be reflected by a shorter lagtime, higher peak height, and shorter ttPeak, and indeed, comparing all trauma patients to healthy volunteers, we have recently shown that the CAT parameters followed this pattern. 15 The overall hypothesis is that the VTE risk prediction score, which utilizes a novel plasma biomarker (ttPeak), will improve the accuracy of identifying patients at high risk for symptomatic VTE than using clinical parameters alone.
METHODS Study Design, Setting, and Population
In a prospective case-cohort study, all trauma patients transported to the Mayo Clinic Emergency Department by ambulance or air transport, as Level 1 or 2 trauma activations, from February 2011 to June 2014 were considered for study inclusion (Table 1) . Exclusion criteria were history of VTE, age <18 years, anticoagulation (e.g., heparin, warfarin) or antithrombotic therapy (excluding aspirin or non-steroidal anti-inflammatory drugs), preexisting coagulopathy, more than 12 hours from time of injury, no blood drawn within the first 12 hours after injury, active cancer, sepsis, renal failure, burn injuries, or declined consent by the patient or legal guardian (Fig. 1) . The time of injury (TOI) was determined by the pre-hospital medical providers based on information at the injury scene. If the TOI was unclear, the pre-hospital medical providers estimated the time and relayed this information to the emergency communication center. A trauma alert page was then sent to the hospital and laboratory staff as to the TOI. We collected demographic, baseline, and time-dependent clinical characteristics, including injury severity score (ISS), patient age and sex, body mass index (BMI), hospital length of stay (LOS), all-cause mortality, and start and stop of anticoagulant-based thromboprophylaxis and other medications affecting coagulation, trauma injury severity score (TRISS), all injury codes from Mayo Clinic Trauma Registry, transfusion data in the prehospital and for entire index hospitalization, IVC filter placement, and standard admission laboratory data (PT, aPTT, INR, hemoglobin, platelet count). Transfusion therapy was mainly based on Mayo Clinic Trauma Center transfusion guidelines but also at the discretion of the medical provider. This study was approved by the Mayo Clinic Institutional Review Board. All patients were followed forward in time from TOI to the earliest of symptomatic, objectively diagnosed VTE, death or other loss to follow-up, or 92 days (about 3 months) post-hospital discharge.
Power Analysis for the Prospective Case-Cohort Study
When the study was designed, it was anticipated that the total number of patients with a recognized VTE within 3 months of the date of trauma would be a minimum of 80 patients. Assuming the minimum of 80 patients are identified, with a twosided test at alpha level = 0.05, there will be 80% (90%) power to detect a hazard ratio (HR) ≥1.87 (2.07) for an association with a binary risk factor present in 50% of the study population. For a binary risk factor present in 20% of the study population, this study could detect a HR ≥2.19 (2.48).
Diagnostic Criteria for Venous Thromboembolism
A diagnosis of incident DVT or PE, either in hospital or within 92 days (365/4, or about 3 months) after hospital discharge, required objectively diagnosed, symptomatic DVTor PE. The diagnosis of VTE required symptoms or signs of acute DVT or PE and a positive diagnostic imaging study (i.e., whole leg compression venous duplex ultrasonography; pulmonary angiography, computed tomographic pulmonary angiography). The Mayo Clinic Trauma Center utilizes a VTE prophylaxis clinical practice guideline, which was constructed with input from the Eastern Association for the Surgery of Trauma and the American College of Chest Physicians guidelines. 16 Routine screening leg venous duplex ultrasonography in search of asymptomatic DVT was not performed. Incident symptomatic, objectively diagnosed arm DVT, proximal or isolated distal leg DVT (occlusive or nonocclusive), and PE were included as outcome events.
The end of day 1 was chosen as a time point, before which development of VTE would be considered non-preventable. This was based on our Institutional and Trauma Division's guidelines to assess for risk of venous thromboembolism within 24 hours of admission. This is consistent with Centers for Medicare and Medicaid Services (CMS) recommendation that patients be assessed for VTE risk within 24 hours after admission. Hence, we reasoned that if the VTE occurred before hospital day 1, it would be considered non-preventable. Lastly, the objective of this study is to assess the utility of CAT assay in predicting eventual development of VTE. As a rural trauma center, about 50% of our trauma patients are from outside Olmsted County and, hence, do not arrive immediately from the scene. Hence, this window of opportunity to collect samples was needed as long as they presented within 12 hours from the time of injury.
Selection of Cohort Patients
During the first 12 months of study enrollment, all the trauma patients enrolled into the study without development of VTE were considered as cohort members during the first 12 months of study. Close to 97% of cohort patient samples that were acquired during this time period were analyzed. During the subsequent years of enrollment, on a quarterly basis, an average of three non-VTE patients had their samples analyzed. Cohort members who developed VTE >92 days after hospital discharge were excluded as cases but were available for selection as a cohort member. CAT assays were performed on stored plasma samples for VTE cases and members of the cohort.
Sample Collection and Processing
Blood samples were collected at baseline (0-2 hours), 6 hours, 12 hours, and days 1 and 3 after injury, and at hospital discharge. When patients were unable to provide consent at the time of the trauma, consent was obtained from the patient or legal guardian within 30 days of hospital discharge; samples were discarded when consent could not be obtained. A total of 18 mL of whole blood was collected by antecubital venipuncture or via existing indwelling catheters into 4.5 mL citrated Vacutainer tubes (0.105 M buffered sodium citrate, 3.2%; Becton Dickinson, Plymouth, UK) and processed to platelet-free plasma by double centrifugation (3,000g, 15 min) as recommended by the ISTH vascular biology SSC Collaborative Workshop, 17 and stored in multiple aliquots at −80°C until analysis. All samples were processed within 1 hour of collection.
Calibrated Automated Thrombogram (CAT) Analyses
Thrombin generation was measured with the calibrated automated thrombogram (CAT; Thrombinoscope BV, Maastricht, The Netherlands), utilizing a Fluoroskan Ascent plate reader (390 nm excitation, 460 nm emission; Thermo Electron Corporation, Vantaa, Finland), as previously described by Hemker et al. 18, 19 and Owen et al. 20 Assays of trauma patient samples were performed in triplicate. Corn trypsin inhibitor (25 mg/mL) 25 μL (50 μg/mL final concentration) was added to each plasma sample before CAT analyses. Thrombin generation was initiated using two different reagents: addition of 20 μL of PPP (5 pM tissue factor and 4 μM phospholipid; Stago, USA) reagent. Then, 80 μL of citrated platelet-poor plasma was added to each well of U bottom 96-well microtiter plates (Nunc; Thermo Fischer Scientific, Rochester, NY) using a single channel pipette. After an incubation period (10 min at 37°C), 20 μL of warmed FLUCA reagent (Fluca kit, TS50; Thrombinoscope, BV), which contains the fluorogenic substrate and CaCl 2 , was added to each well via an automated dispenser. Thrombin generation curves were recorded continuously for 90 minutes at a rate of 3 readings per minute. Separate wells containing the thrombin calibrator, which corrects for inner filter effects and quenching variation among individual plasmas, were also measured in parallel. A dedicated program, Thrombinoscope, was used to calculate thrombin activity over time. The parameters derived were lagtime (LT), time to peak (ttPeak), and peak height (PH). We did not analyze samples collected after anticoagulantbased (mainly heparin) prophylaxis as prophylactic dose of heparin completely attenuated thrombin generation in CAT analyses. When unfractionated heparin was added to platelet-poor plasma (Cryocheck) at final concentrations varying from 0.1 to 0.4 U/mL, we noted a significant decrease in PH values (85% decrease) and prolongation of LT (200% increase), even at the lowest dose.
Statistical Analyses
Data analysis was performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC) and R version 3.2.0. Descriptive statistics are presented as median values (interquartile range). Comparisons of variables between VTE cases and cohort members were done using the Kruskal-Wallis and Fisher's exact tests. For each laboratory test, the first plasma sample for each patient analyzed for CAT was identified. This value was used in univariable and multivariable assessments of association with freedom from VTE using Cox proportional hazards regression, with results presented as hazard ratio (HR) with 95% CI. Weighted Cox model, using Barlow weights, was used to account for the fact that all cases but only a fraction of cohort members (370 out of total 1,151) were included in the analyses. 21 Cox modeling was done with time to VTE as the endpoint and death as a censoring event. We also performed univariable and multivariable Cox proportional hazards regressions using the most "hypercoagulable" (shortest ttPeak) value within the first 24 hours for each patient who had multiple samples. Clinical variables adjusted for in multivariable analysis were those easily obtainable within 24 hours of admission and strongly related to symptomatic VTE (p < 0.05) on a univariate basis. For each model, the concordance (C-) statistic adapted to survival analysis was used as a descriptive measure of predictive power. Risk scores were derived based on the linear combination of variables using their coefficients in the Cox proportional hazards regression. To describe the impact of CAT parameter (in particular, ttPeak) on reclassification, we used a ROC analyses of the binary version of the outcome (VTE: yes or no) to select a score cutoff with highest sensitivity and specificity. The alpha level was set at 0.05 for statistical significance.
RESULTS
Over the 4.5-year period, February 2011 to September 2015, 2,954 patients with acute trauma were screened for study enrollment; 1,960 met study inclusion criteria of which 1,234 (63%) consented to participate (Fig. 1) In an effort to ensure that the analyzed group was representative of all patients enrolled into our study, the 370 (after excluding the 83 VTE patients) patients whose plasma samples were analyzed were compared to the 781 (all of whom being non-VTE patients) who were enrolled but did not have their plasma analyzed. There were no statistical differences between the two groups: age (47 [26, 62] , 47 [30, 62]; p = 0.300), male sex percentage (70, 70; p = 0.870), percentage of blunt mechanism of injury (96, 96, p = 0.838), and ISS (12 [5, 19] , 11 [6, 17] ; p = 0.807).
Of these, 83 developed VTE within 92 days after trauma; 11 patients developed VTE within day 1 and 35 patients (42%) developed VTE after hospital discharge. At end of day 1 of admission, 34% and 57% of patients had been placed on chemoand mechanical prophylaxis, respectively. Overall, 67.5% VTE patients and 52.7% random cohort patients, whose plasma samples were analyzed, received chemoprophylaxis during their hospital admission (p = 0.015). For mechanical prophylaxis, there were no significant differences between these two groups (56.3% and 65.4%, respectively; p = 0.164). Demographic and baseline characteristics of VTE cases and cohort members are outlined in Table 2 . We analyzed 1,600 samples collected from the 83 patients who developed VTE and 370 cohort members without VTE. Overall, 236 patients had their first blood sample drawn at baseline, 191 had 6 hours, and 24 at 12 hours. The median time of first blood draw was 2.3 hours (1.25, 5.85). There were a total of 35 IVC filters placed in VTE patients: 22 as "prophylaxis", 2 after acute PE, 8 after acute DVT, and 3 after both PE and DVT. Among the 22 patients who had a "prophylactic" IVC filter placed, 2 developed PE and 20 developed DVT after filter placement. Of the 83 VTE cases, 11 patients developed VTE by the end of day 1 and were considered to have nonpreventable VTE (2 patients with diagnosis of PE, 3 for DVT, 6 for both PE and DVT). Hence, the following analyses were based on the remaining 72 VTE cases. In a univariable analysis of the prospective cohort data, several clinical variables which were available within 24 hours of admission, as well as ttPeak and Lagtime data obtained from the first blood sample in each patient after injury were predictors of incident VTE ( In a receiver operator characteristic curve analysis, based on simplifying the end-point from time-to-event to a binary variable, the optimal VTE risk score cutoff gave the best sensitivity and specificity of 74% and 73%, respectively. Hence, a patient at end of day 1 of admission who has a VTE risk score greater than the optimal cutoff would be considered to be at "High-Risk" for VTE in the ensuing 92 days. This definition led to 52 true positives, 18 false negatives, 87 false positives, and 239 true negatives. The addition of ttPeak more accurately predicted VTE than using clinical variables alone (in our case, BMI, age, any surgery). Specifically, we were able to identify (net) five more true VTE cases and five more true VTE negative patients, reducing the rate of misclassification by 8.7% (10/115) because of ttPeak datum in the model (Table 5) . We also tested the most hypercoagulable CAT variable (ttPeak). Similar to using the first ttPeak value, we again observed an improvement (9.6%) in misclassification when each patient's most hypercoagulable ttPeak value (C-statistic of 0.794) was used, when compared to the clinical-only model. Almost 56% of patients who had multiple blood samples had the most hypercoagulable sample during their first blood draw.
DISCUSSION
This is the first study to show that an individual's plasma coagulome as reflected by thrombin generation (CAT) can be *N equals to number of data points available from VTE cases and from those whose follow-up was greater than 1 day (total of 429 patients). **Using reagents 5 pM TF/4 μM PS; Any surgery-any procedure performed in the operating room and requires general anesthesia; Any fracture-includes upper, lower pelvic, and spine fractures; TRISS-trauma injury severity score (probability of survival).
†Admission laboratories. ‡To note, only 23 patients (15 No-VTE and 8 Yes-VTE) had IVC filters placed by end of day 1 of hospitalization. used to predict VTE after trauma. Current guidelines recommend VTE prophylaxis for all trauma patients, a patient population at high risk for bleeding. The literature is replete with well-designed work elucidating risk factors for VTE in trauma patients. [22] [23] [24] [25] However, follow-up often is limited to the duration of hospitalization. In our prospective case-cohort study, we observed that 42% of cases developed VTE after hospital discharge. We recently published a retrospective population-based, casecohort study of Olmsted County trauma patients in whom postdischarge symptomatic VTE rate was 62%. 26 These observations are very similar to findings by Godat et al., who showed that the period of VTE risk after acute injury persists for 3 months after injury. 27 Additionally, the peak endogenous thrombin generation formed more quickly as compared to non-VTE patients very early after injury. In particular, ttPeak value seems to be an independent predictor of VTE and helped us to identify (net) five more true VTE cases and five more true VTE negative patients, reducing the rate of misclassification by 8.7%. Hence, acceleration of thrombin generation is important in generating the hypercoagulable milieu needed for thrombotic complications. In our multivariable model, Z-scores for the beta coefficients were on the order of 3 to 4, indicating high power to detect them again in a new sample of similar size. Currently, no appropriately validated tools that take into account individual patient's coagulation phenotype are available to identify the individual trauma patient at high risk for VTE. Our multivariable model shows that ttPeak improves the concordance statistic by 4.5% from 0.754 to 0.799. Interestingly, our initial focus on generating the model was using the most hypercoagulable ttPeak (shortest) value as most patients had multiple samples drawn during the study. What we have found is that using each patient's first available ttPeak value, as long as it is within first 12 hours of injury, is as superior as picking the most hypercoagulable ttPeak value. Hence, CAT can be a laboratory test with a translatable potential.
Our study has several limitations. First, our overall consent rate was approximately 63%. As with all observational studies, sampling bias was a concern in our study and potentially affects the estimate of the relative risk in our observational study. However, the enrolled patients were reflective of the excluded population of 1,720 patients (≥18 years old) seen at our Trauma Center during the study period in regards to median age (48 [28, 68]), sex (69% men), and mechanism of injury (93% blunt). When patients or their legal surrogates were approached in person, our overall consent rate has been 80%. When patients are approached via mail, after their initial discharge, the overall consent rate has been consistently 20%. The best way to prevent sampling bias is achieving a high response rate, which requires intensive efforts. In the present study, we devised a standard protocol in which surveys were mailed close to 3 months after injury, followed by phone calls utilizing a standard template of questions (to reduce the risk of measurement bias). Second, 97% cohort patients were chosen from those enrolled during the first 12 months of the study. Because of budget limits and lack of additional power added by analyzing all the cohort samples, plasma samples from few cohort patients were analyzed after the initial 12 months of the study enrollment. Hence, our cohort patients were not truly randomly selected throughout the study period. To ensure that the 370 cohort patients (whose plasma samples were analyzed) were representative of all cohort patients enrolled into our study, we compared the ISS, age, male sex percentage, and mechanism of injury and found no significant differences between the two groups. Lastly, we could have added more variables such as ISS and TRISS into the final model, potentially improving the concordance rate. We intentionally wanted to generate a model that utilizes clinical variables that are easily obtainable and CAT assay, which theoretically would be ordered as a batched laboratory test. We hope that our model is generalizeable as a result of its use of easy-to-obtain clinical variables.
In a future study, we plan to validate our VTE risk assessment tool ("24 hour tool"), which incorporates readily obtainable clinical risk factors and the individual patient's plasma coagulome (as reflected in ttPeak via CAT). In our completed prospective cohort study, 42% VTE cases occurred after hospital discharge. Universally extending prophylaxis beyond discharge will increase the bleeding risk period. A better strategy is to intensively prophylax the high-VTE-risk individual who would benefit most and potentially avoid the complications of anticoagulant-based VTE prophylaxis in the low-VTE-risk individual with trauma. If we are able to validate this tool, we hope to perform a clinical trial to test the efficacy (non-inferiority for efficacy [endpoints will be DVT, PE, or sudden death]) and safety (superiority for safety [endpoints will be bleeding and wound infection]) of the VTE risk prediction tool in individual with acute trauma.
CONCLUSION
Our VTE risk tool, which incorporates easily obtainable clinical risk factors, as well as the individual patient's procoagulant phenotype (as reflected by thrombin generation via CAT), will more accurately predict the occurrence of symptomatic VTE after injury. Alarmingly, we have observed that 42% of our cases developed VTE after hospital discharge. However, universally extending prophylaxis beyond discharge will increase the bleeding risk period. A better strategy would be to target more effective prophylaxis to the trauma patients at high risk for VTE. Our VTE risk assessment tool needs to be validated. 
